Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.657.195 €): Calcium-Sensing-Rezeptor (CaSR): Therapeutika für nichtübertragbare Krankheiten Hor 20.07.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Calcium-Sensing-Rezeptor (CaSR): Therapeutika für nichtübertragbare Krankheiten
The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular disease (CVD), diabetes (DM), sarcopenia and cancer, which account for >25% of the global disease burden. The CaSR is a unique GPCR whose principal physiological ligand is the Ca2+ ion; it is expressed almost ubiquitously; interacts with multiple Gα subtypes regulating highly divergent downstream signalling pathways, depending on the cellular context. The CaSR Biomedicine is a fully translational project that utilises the concept of a single molecule, the CaSR, influencing a range of physiological and disease processes, to develop a unique, strong multidisciplinary and intersectoral scientific training programme preparing 14 young scientists to become specialists in GPCR biology and signalling. The objectives of CaSR Biomedicine are: 1. Educate and train Early Stage Researchers to become highly innovative scientists to enhance their career perspective. 2. Elucidate ligand- and tissue-dependent differences in CaSR physiology by examining its functions at cellular level and thus to contribute to the understanding of GPCR signalling in general; 3. Assess how CaSR function is altered in AD, CVD, DM, sarcopenia, and cancer, and to find innovative CaSR-based therapeutic approaches for these major, age-related disorders. 4. Establish long-lasting interdisciplinary and intersectoral cooperation among researchers and between researchers and industry, to strengthen the European Research Area. Therefore the CaSR Biomedicine will investigate the complexity of CaSR signalling and function to identify CaSR-based therapeutic approaches to diseases linked to changes in CaSR expression or function (AD, CVD, DM, sarcopenia, and cancer).
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| AHT-Management | ? |
| Biotalentum Tudasfejleszto kft. | 223.914 € |
| Cardiff University | 273.288 € |
| Fundacio Privada Per A La Recerca i La Docencia Sant Joan de Deu | 247.873 € |
| Kobenhavns Universitet | 290.082 € |
| Medizinische Universitaet Wien | 511.868 € |
| S.A.F.AN. Bioinformatics - SAS Di Pugliese Luisa | 258.061 € |
| Stichting VU | 255.374 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 273.288 € |
| The University of Liverpool | 273.288 € |
| The University of Manchester | 273.288 € |
| Tissuegnostics GmbH | 255.934 € |
| Universita Degli Studi Di Firenze | 258.061 € |
| Universite de Picardie Jules Verne | 262.876 € |
Quelle: https://cordis.europa.eu/project/id/675228
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: AHT-Management, Budapest, Ungarn.